Loading...
XASX
ACR
Market cap4mUSD
Oct 09, Last price  
0.01AUD
1D
10.00%
1Q
0.00%
Jan 2017
-96.45%
IPO
-98.72%
Name

Acrux Ltd

Chart & performance

D1W1MN
XASX:ACR chart
P/E
—
P/S
1.40
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.99%
Rev. gr., 5y
28.28%
Revenues
5m
+290.25%
2,897,0004,496,000650,00054,904,00089,603,0008,797,00015,549,00053,859,00025,368,00028,557,00023,934,0003,432,000631,0001,253,0001,337,0001,719,0008,429,0005,091,0001,190,0004,644,000
Net income
-604k
L-89.84%
-7,860,000-5,026,000-7,716,00046,554,00057,148,0007,391,0006,926,00027,970,00011,130,00012,981,000-243,000-14,182,000-8,325,000-9,471,000-12,629,000-9,834,000-764,000-5,800,000-5,945,000-604,000
CFO
1m
P
-7,698,000-2,713,000-5,781,00048,119,00065,104,000-2,432,0006,335,00036,371,00010,519,00016,506,0005,376,000-5,282,000-9,938,000-8,533,000-11,414,000-8,819,000703,000-4,303,000-5,471,0001,018,999
Dividend
Aug 18, 20150.06 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels. Additionally, Acrux provides estradiol sprays, sold under the brand names Evamist and Lenzetto, specifically formulated for women experiencing hot flashes associated with menopause. The company, established in 1998, is headquartered in West Melbourne, Australia.

Key people

Michael Kotsanis
Chief Executive Officer, Managing Director, Executive Director · since 2014
Deborah Ambrosini
Chief Financial Officer, Company Secretary · since 2019
Felicia Colagrande
Product Development and Technical Affairs Director · since 2015
Charles O'Sullivan
Portfolio Director · since 2015
Commercial Director · since 2018
Independent Non-Executive Chairman of the Board · since 2014
Non-Executive Independent Director · since 2016
Timothy Charles Oldham
Non-Executive Independent Director · since 2013
IPO date
Sep 29, 2004
Employees
43
Domiciled in
AU
Incorporated in
AU
Legal address
103-113 Stanley St
West Melbourne, VIC 3003
AU
Headquarters
103-113 Stanley St
West Melbourne, ACT 3003
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT